| x | QUARTERLY                  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES ACT OF                  1934 |
|---|------------------------------------------------------------------------------------------------------------|

| o | TRANSITION                  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES ACT OF                  1934 |
|---|-------------------------------------------------------------------------------------------------------------|

----

| Nevada                                                                          |   | 87-0650264                                            |
|---------------------------------------------------------------------------------|--------|-------------------------------------------------------|
| (State                  or Other Jurisdiction of Incorporation or Organization) |   | (I.R.S.                  Employer Identification No.) |
|                                                                            |   |                                                  |

----

----

|                                                            |                                                                                                                                                 |
|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| PART                  I. FINANCIAL                  INFORMATION |                                                                                                                                                 |
|                                                            |                                                                                                                                                 |   |
| Item                  1.                                        | Financial                  Statements                                                                                                                | 3 |
|                                                            | Condensed                  Consolidated Balance Sheet as of September 30, 2005                  (unaudited)                                          | 3 |
|                                                            | Condensed                  Consolidated Statements of Operations for the three                  and nine-months ended September 30, 2005 (unaudited) | 4 |
|                                                            | Condensed                  Consolidated Statements of Cash Flows for the                  nine-months ended September 30, 2005 (unaudited)           | 5 |
|                                                            | Notes                  to Condensed Consolidated Financial                  Statements                                                               | 6 |
|                                                            |                                                                                                                                                 |   |
| Item                  2.                                        | Management's                  Discussion and Analysis or Plan of                  Operation                                                          | 12 |
|                                                            |                                                                                                                                                 |   |
| Item                  3.                                        | Controls                  and Procedures                                                                                                             | 17 |
|                                                            |                                                                                                                                                 |   |
| PART                  II. OTHER INFORMATION                     |                                                                                                                                                 |
|                                                            |                                                                                                                                                 |   |
| Item                  1.                                        | Legal                  Proceedings                                                                                                                   | 17 |
|                                                            |                                                                                                                                                 |   |
| Item                  2.                                        | Unregistered                  Sales of Equity Securities and Use of                  Proceeds                                                        | 18 |
|                                                            |                                                                                                                                                 |   |
| Item                  3.                                        | Defaults                  Upon Series Securities                                                                                                     | 18 |
|                                                            |                                                                                                                                                 |   |
| Item                  4.                                        | Submission                  of Matters to a Vote of Security                  Holders                                                                | 18 |
|                                                            |                                                                                                                                                 |   |
| Item                  5.                                        | Other                  Information                                                                                                                   | 18 |
|                                                            |                                                                                                                                                 |   |
| Item                  6.                                        | Exhibits                  and Reports on Form 8-K                                                                                                    | 19 |
|                                                            |                                                                                                                                                 |   |
| SIGNATURES                                                      |                                                                                                                                                 | 20 |

----

**PART        I. FINANCIAL INFORMATION**

**Item        1. Financial Statements**

CONDENSED        CONSOLIDATED BALANCE SHEET

| **ASSETS**                                                                                                  |   |        |   |   |   |
|-------------------------------------------------------------------------------------------------------------|--------|--------|--------|--------|--------|
| **CURRENT                    ASSETS**                                                                       |   |   |   |   |   |
| Cash                    and cash equivalents                                                           |   |   |   |   | $      | 240,124 |   |
| Accounts                    receivable                                                                 |   |   |   |   |   | 592,678 |   |
| Inventories,                    net                                                                    |   |   |   |   |   | 1,551,852 |   |
| Loans                    receivable                                                                    |   |   |   |   |   | 431,566 |   |
| Due                    from stockholders                                                               |   |   |   |   |   | 107,734 |   |
| Other                    receivables                                                                   |   |   |   |   |   | 459,484 |   |
|  Total                    Current Assets                                                               |   |   |   |   |   | 3,383,438 |   |
|                                                                                                        |   |   |   |   |   |   |   |
| **PROPERTY                    AND EQUIPMENT, NET**                                                          |   |   |   |   |   | 2,345,528 |   |
|                                                                                                        |   |   |   |   |   |   |   |
| **LAND                    USE RIGHTS, NET**                                                                 |   |   |   |   |   | 131,914 |   |
| **TOTAL                    ASSETS**                                                                         |   |   |   |   | $      | 5,860,880 |   |
|                                                                                                        |   |   |   |   |   |   |   |
|                                                                                                        |   |   |   |   |   |   |   |
| **LIABILITIES                    AND STOCKHOLDERS' EQUITY**                                                 |   |   |   |   |   |   |   |
|                                                                                                        |   |   |   |   |   |   |   |
| **CURRENT                    LIABILITIES**                                                                  |   |   |   |   |   |   |   |
| Accounts                    payable                                                                    |   |   |   |   | $      | 57,640 |   |
| Bill                    payable                                                                        |   |   |   |   |   | 31,936 |   |
| Other                    payables and accrued expenses                                                 |   |   |   |   |   | 120,295 |   |
| Income                    tax and other tax payables                                                   |   |   |   |   |   | 39,765 |   |
| Convertible                    note payable                                                            |   |   |   |   |   | 1,900,000 |   |
| Due                    to stockholders                                                                 |   |   |   |   |   | 1,233 |   |
|  Total                    Current Liabilities                                                          |   |   |   |   |   | 2,150,869 |   |
|                                                                                                        |   |   |   |   |   |   |   |
| **COMMITMENTS                    AND CONTINGENCIES**                                                        |   |   |   |   |   | - |   |
|                                                                                                        |   |   |   |   |   |   |   |
| **MINORITY                    INTEREST**                                                                    |   |   |   |   |   | 474,044 |   |
|                                                                                                        |   |   |   |   |   |   |   |
| **STOCKHOLDERS'                    EQUITY**                                                                 |   |   |   |   |   |   |   |
| Preferred                    stock, $0.001 par value, 5,000,000 shares                    authorized,  |   |   |   |   |   |   |   |
|  non                    issued and outstanding                                                         |   |   |   |   |   | - |   |
| Common                    stock, $0.001 par value, 100,000,000 shares authorized,                      |   |   |   |   |   |   |   |
| 93,604,958                    shares issued and outstanding                                                 |   |   |   |   |   | 93,605 |   |
| Additional                    paid-in capital                                                          |   |   |   |   |   | 4,998,849 |   |
| Retained                    earnings (deficit)                                                         |   |   |   |   |   |   |   |
| Unappropriated                                                                                         |   |   |   |   |   | (1,927,388 | ) |
| Appropriated                                                                                           |   |   |   |   |   | 7,250 |   |
| Accumulated                    other comprehensive income                                              |   |   |   |   |   | 63,651 |   |
|  Total                    Stockholders' Equity                                                         |   |   |   |   |   | 3,710,011 |   |
|                                                                                                        |   |   |   |   |   |   |   |
| **TOTAL                    LIABILITIES AND STOCKHOLDERS' EQUITY**                                           |   |   |   |   | $      | 5,860,880 |   |

----

CONDENSED        CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE        INCOME

|                                                          |   | For                    the Three                         |       | For                    the Three                         |   | For                    the Nine                          |   | For                    the Nine                          |       |
|---------------------------------------------------------------|--------|----------------------------------------------------------|------------|----------------------------------------------------------|--------|----------------------------------------------------------|--------|----------------------------------------------------------|------------|
|                                                          |   | Months                    Ended                          |       | Months                    Ended                          |   | Months                    Ended                          |   | Months                    Ended                          |       |
|                                                          |   | September                    30,                    2005 |       | September                    30,                    2004 |   | September                    30,                    2005 |   | September                    30,                    2004 |       |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |
| **NET                    SALES**                              |   | $                                                        | 638,442    |                                                     | $      | 570,618                                                  |   | $                                                        | 1,981,254  |   | $ | 1,784,130 |   |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **COST                    OF SALES**                          |   |                                                     | (478,273   | )                                                        |   | (483,650                                                 | )      |                                                     | (1,571,976 | ) |   | (1,565,712 | ) |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **GROSS                    PROFIT**                           |   |                                                     | 160,169    |                                                     |   | 86,968                                                   |   |                                                     | 409,278    |   |   | 218,418 |   |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **OPERATING                    EXPENSES**                     |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| Selling                    expenses and distribution expenses |   |                                                     | 33,614     |                                                     |   | 11,423                                                   |   |                                                     | 82,319     |   |   | 27,426 |   |
| General                    and administrative expenses        |   |                                                     | 66,849     |                                                     |   | 13,837                                                   |   |                                                     | 154,599    |   |   | 28,411 |   |
| Depreciation                    and amortization              |   |                                                     | 44,275     |                                                     |   | 9,383                                                    |   |                                                     | 79,045     |   |   | 30,660 |   |
| Total                    Operating Expenses                   |   |                                                     | 144,738    |                                                     |   | 34,643                                                   |   |                                                     | 315,963    |   |   | 86,497 |   |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **INCOME                    FROM OPERATIONS**                 |   |                                                     | 15,431     |                                                     |   | 52,325                                                   |   |                                                     | 93,315     |   |   | 131,921 |   |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **OTHER                    INCOME (EXPENSE)**                 |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| Equity                    in loss of affiliate                |   |                                                     | -          |                                                     |   | (53                                                      | )      |                                                     | (112       | ) |   | (53 | ) |
| Goodwill                    written off                       |   |                                                     | -          |                                                     |   | -                                                        |   |                                                     | (2,764     | ) |   | - |   |
| Interest                    income, net                       |   |                                                     | 12,325     |                                                     |   | 1,163                                                    |   |                                                     | 19,962     |   |   | 800 |   |
| Other                    income (expense), net                |   |                                                     | -          |                                                     |   | 55                                                       |   |                                                     | 42,270     |   |   | (1,052 | ) |
| Total                    Other Income (expense)               |   |                                                     | 12,325     |                                                     |   | 1,165                                                    |   |                                                     | 59,356     |   |   | (305 | ) |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **INCOME                    FROM OPERATIONS BEFORE**          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **TAXES                    AND MINORITY INTEREST**            |   |                                                     | 27,756     |                                                     |   | 53,490                                                   |   |                                                     | 152,671    |   |   | 131,616 |   |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **INCOME                    TAX EXPENSE**                     |   |                                                     | (12,858    | )                                                        |   | 13,275                                                   |   |                                                     | (38,670    | ) |   | (5,466 | ) |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **MINORITY                    INTEREST**                      |   |                                                     | (5,437     | )                                                        |   | 2,138                                                    |   |                                                     | (41        | ) |   | 6,325 |   |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **NET                    INCOME**                             |   |                                                     | 9,461      |                                                     |   | 68,903                                                   |   |                                                     | 113,960    |   |   | 132,475 |   |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **OTHER                    COMPREHENSIVE INCOME**             |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| Foreign                    currency translation income        |   |                                                     | 63,651     |                                                     |   | -                                                        |   |                                                     | 63,651     |   |   | - |   |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **COMPREHENSIVE                    INCOME**                   |   | $                                                        | 73,112     |                                                     | $      | 68,903                                                   |   | $                                                        | 177,611    |   | $ | 132,475 |   |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| **Net                    income per share - diluted**         |   | $                                                        | -          |                                                     | $      | -                                                        |   | $                                                        | -          |   | $ | - |   |
|                                                          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| Weighted                    average number of shares          |   |                                                     |       |                                                     |   |                                                     |   |                                                     |       |   |   |   |   |
| outstanding                    during the period - diluted    |   |                                                     | 93,604,958 |                                                     |   | 80,735,590                                               |   |                                                     | 93,604,958 |   |   | 80,735,590 |   |

----

CONDENSED        CONSOLIDATED STATEMENTS OF CASH FLOWS

|                                                                              |   | For                      the Nine       |       | For                      the Nine       |   |
|-----------------------------------------------------------------------------------|--------|-----------------------------------------|------------|-----------------------------------------|--------|
|                                                                              |   | Months                      Ended       |       | Months                      Ended       |   |
|                                                                              |   | September                      30, 2005 |       | September                      30, 2004 |   |
| **CASH                      FLOWS FROM OPERATING ACTIVITIES**                     |   |                                    |       |                                    |   |
| Net                      income                                              |   |                                    | 113,960    |                                    |   | 132,475 |   |
| Adjusted                      to reconcile net income to net cash provided   |   |                                    |       |                                    |   |   |   |
|  by                      (used in) operating activities:                     |   |                                    |       |                                    |   |   |   |
|  Depreciation                      and amortization - cost of sales          |   |                                    | 82,175     |                                    |   | 44,283 |   |
|  Depreciation                      and amortization                          |   |                                    | 79,045     |                                    |   | 30,660 |   |
|  Equity                      in loss of affiliate                            |   |                                    | 31,190     |                                    |   | (31,348 | ) |
|  Minority                      interest                                      |   |                                    | 415,129    |                                    |   | (6,326 | ) |
| Changes                      in operating assets and liabilities             |   |                                    |       |                                    |   |   |   |
|  (Increase)                      decrease in:                                |   |                                    |       |                                    |   |   |   |
|  Accounts                      receivable, net                               |   |                                    | (488,534   | )                                       |   | 49,604 |   |
|  Inventories                                                                 |   |                                    | (249,827   | )                                       |   | (188,812 | ) |
|  Due                      from stockholders                                  |   |                                    | (45,241    | )                                       |   | 364,224 |   |
|  Other                      receivables                                      |   |                                    | (124,426   | )                                       |   | (465,706 | ) |
|  Increase                      (decrease) in:                                |   |                                    |       |                                    |   |   |   |
|  Accounts                      payable                                       |   |                                    | 1,186      |                                    |   | 68,864 |   |
|  Bill                      payable                                           |   |                                    | 31,936     |                                    |   | - |   |
|  Other                      payables and accrued expenses                    |   |                                    | (24,896    | )                                       |   | 27,882 |   |
|  Value                      added tax payable                                |   |                                    | (12,323    | )                                       |   | - |   |
|  Income                      tax and other taxes payable                     |   |                                    | 33,081     |                                    |   | 4,952 |   |
|  Due                      to stockholders                                    |   |                                    | (192,200   | )                                       |   | - |   |
|  Net                      cash (used in) provided by operating activities    |   |                                    | (349,745   | )                                       |   | 30,752 |   |
|                                                                              |   |                                    |       |                                    |   |   |   |
| **CASH                      FLOWS FROM INVESTING ACTIVITIES**                     |   |                                    |       |                                    |   |   |   |
| Decrease                      in notes receivable                            |   |                                    | -          |                                    |   | 506,774 |   |
| Purchase                      of property and equipment                      |   |                                    | (1,625,185 | )                                       |   | (65,562 | ) |
|  Net                      cash (used in) provided by investing activities    |   |                                    | (1,625,185 | )                                       |   | 441,212 |   |
|                                                                              |   |                                    |       |                                    |   |   |   |
| **CASH                      FLOWS FROM FINANCING ACTIVITIES**                     |   |                                    |       |                                    |   |   |   |
| Registered                      capital appropriation                        |   |                                    | 2,415,458  |                                    |   | - |   |
| Increase                      in loans receivable                            |   |                                    | (431,566   | )                                       |   | - |   |
| Decrease                      in notes payable                               |   |                                    | -          |                                    |   | (241,642 | ) |
|  Net                      cash provided by (used in) financing activities    |   |                                    | 1,983,892  |                                    |   | (241,642 | ) |
|                                                                              |   |                                    |       |                                    |   |   |   |
| **EFFECT                      OF EXCHANGE RATES ON CASH**                         |   |                                    | 63,651     |                                    |   | - |   |
|                                                                              |   |                                    |       |                                    |   |   |   |
| **NET                      INCREASE IN CASH AND CASH EQUIVALENTS**                |   |                                    | 72,613     |                                    |   | 230,322 |   |
|                                                                              |   |                                    |       |                                    |   |   |   |
| **CASH                      AND CASH EQUIVALENTS AT BEGINNING OF PERIOD**         |   |                                    | 167,511    |                                    |   | 95,803 |   |
|                                                                              |   |                                    |       |                                    |   |   |   |
| **CASH                      AND CASH EQUIVALENTS AT END OF PERIOD**               |   |                                    | 240,124    |                                    |   | 326,125 |   |
|                                                                              |   |                                    |       |                                    |   |   |   |
| **SUPPLEMENTAL                      DISCLOSURE OF CASH FLOW INFORMATION**         |   |                                    |       |                                    |   |   |   |
|                                                                              |   |                                    |       |                                    |   |   |   |
| Cash                      paid during the year for:                               |   |                                    |       |                                    |   |   |   |
| Income                      taxes                                            |   | $                                       | -          |                                    | $      | - |   |
|                                                                              |   |                                    |       |                                    |   |   |   |
| Interest                      expenses                                       |   | $                                       | 1,618      |                                    | $      | - |   |
|                                                                              |   |                                    |       |                                    |   |   |   |

----

**(HUIFENG        BIO-PHARMACEUTICAL TECHNOLOGY INC. **

**(FORMERLY        KNOWN AS SECURED DATA, INC.) AND SUBSIDIARIES**

**NOTES        TO CONDENSED CONSOLIDATED FINANCIAL        STATEMENTS**

**(UNAUDITED)**

**SEPTEMBER        30, 2005**

----

| **NOTE                  1** | **ORGANIZATION                    AND BASIS OF                    PRESENTATION** |
|-----------------------------|----------------------------------------------------------------------------------|

----

|  | (1) | The                    balance sheets as of September 30, 2005 (unaudited) and December                    2004                    consist of the net assets of the acquirer at historical cost                    and the net                    assets of the acquiree at historical                    cost. |
|--|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (2) | The                    statements of operations for the three and nine months ended                    September 30,                    2005 (unaudited) includes the operations of the acquirer for                    the periods                    presented and the operations of the acquiree from the date of                    the                    merger. |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **NOTE                2** | **ACQUISITION** |
|---------------------------|-----------------|

| **NOTE                3** | **PRINCIPLES                  OF CONSOLIDATION** |
|---------------------------|--------------------------------------------------|

----

| **NOTE                4** | **USE                  OF ESTIMATES** |
|---------------------------|---------------------------------------|

| **NOTE                5** | **EARNINGS                  PER SHARE** |
|---------------------------|-----------------------------------------|

| **NOTE                6** | **ACQUISITION                  OF SUBSIDIARY** |
|---------------------------|------------------------------------------------|

|                                                                              |   |   |      |   |
|-----------------------------------------------------------------------------------|--------|--------|-----------|--------|
| Current                    assets                                                 |   | $      | 582,743   |   |
| Non-current                    assets                                             |   |   | 1,526,118 |   |
| Total                    assets                                                   |   |   | 2,108,861 |   |
| Current                    liabilities                                            |   |   | (10,870   | )      |
| Net                    assets acquired                                            |   |   | 2,097,991 |   |
|                                                                              |   |   |      |   |
| Minority                    interest                                              |   |   | (415,088  | )      |
|                                                                              |   |   | 1,682,903 |   |
| Share                    of pre-acquisition losses prior to becoming a subsidiary |   |   | 323       |   |
|                                                                              |   |   | 1,683,226 |   |
| Goodwill                    acquired                                              |   |   | 2,764     |   |
| Consideration                    paid                                             |   | $      | 1,685,990 |   |

----

| **NOTE                7** | **GOODWILL** |
|---------------------------|--------------|

|                                                                             |   | 2005        |    |   |   |
|----------------------------------------------------------------------------------|--------|-------------|---------|--------|--------|
|                                                                             |   | (Unaudited) |    | 2004   |   |
|                                                                             |   |        |    |   |   |
| Cost                    of goodwill acquired in step acquisition of a subsidiary |   | $           | 2,764   |   | $      | – |   |
| Amount                    written off                                            |   |        | (2,764  | )      |   | – |   |
|                                                                             |   | $           | – |   | $      | – |   |

| **NOTE                8** | **LOANS                  RECEIVABLE** |
|---------------------------|---------------------------------------|

|                                                                                                                                      |   | 2005        |    |   |   |
|-------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------|---------|--------|--------|
|                                                                                                                                      |   | (Unaudited) |    | 2004   |   |
|                                                                                                                                      |   |        |    |   |   |
| Loan                    receivable from a third party, interest rate of 12% per annum,                    non-secured, due September 2005 |   |        | 184,957 |   |   | – |   |
| Loan                    receivable from a third party, interest rate of 10% per annum,                    non-secured, due November 2005  |   |        | 246,609 |   |   | – |   |
|                                                                                                                                      |   |        | 431,566 |   |   | – |   |

| **NOTE                9** | **CONVERTIBLE                  NOTE PAYABLE** |
|---------------------------|-----------------------------------------------|

|                                        |   | 2005        |      |   |   |
|---------------------------------------------|--------|-------------|-----------|--------|--------|
|                                        |   | (Unaudited) |      | 2004   |   |
|                                        |   |        |      |   |   |
| Convertible                    note payable |   | $           | 1,900,000 |   | $      | 1,900,000 |   |
|                                        |   |        |      |   |   |   |   |

----

| **NOTE                10** | **COMMITMENTS                  AND CONTINGENCIES**  |
|----------------------------|----------------------------------------------------------|

|  | **(A)** | **Employee                  benefits** |
|--|---------|----------------------------------------|

|  | **(B)** | **Commitments** |
|--|---------|-----------------|

| 2006   |   | $      | 6,288  |   |
|--------|--------|--------|--------|--------|
|   |   |   |   |   |

| **NOTE                    11** | **STOCKHOLDERS’                      EQUITY** |
|--------------------------------|-----------------------------------------------------|

|  | **(A)** | **Stock                  issuances** |
|--|---------|--------------------------------------|

|  | **(B)** | **Capital                    contribution** |
|--|---------|---------------------------------------------|

|  | **(C)** | **Appropriated                    retained earnings** |
|--|---------|-------------------------------------------------------|

----

| **NOTE                12** | **RELATED                  PARTY TRANSACTIONS** |
|----------------------------|-------------------------------------------------|

| **NOTE                13** | **CONCENTRATIONS                  AND RISKS** |
|----------------------------|-----------------------------------------------|

----

**Item        2. Management's Discussion and Analysis or Plan of        Operation.**

----

**CRITICAL        ACCOUNTING POLICIES AND ESTIMATES**

| 1. | Persuasive                  evidence of an arrangement exists; |
|----|----------------------------------------------------------------|

| 2. | Delivery                  has occurred or services have been                  rendered; |
|----|-----------------------------------------------------------------------------------------|

| 3. | The                  seller's price to the buyer is fixed or determinable;                  and |
|----|-------------------------------------------------------------------------------------------------|

| 4. | Collectibility                  is reasonably assured. |
|----|--------------------------------------------------------|

----

**RESULTS        OF OPERATIONS**

|                                            |   |                                                                 |    |                          |   |
|-------------------------------------------------|--------|----------------------------------------------------------------------|---------|-------------------------------|--------|
|                                            |   | For                    quarter endedSeptember                    30, |    | Increase                    / |   |
| Product                                         |   | 2005                                                                 |    | 2004                          |   |  (Decrease) |   |
|                                            |   |                                                                 |    |                          |   |   |   |
| Pharmaceutical                    intermediates |   | $                                                                    | 541,443 |                          | $      | 486,288 |   | $ | 55,155 |   |
| Pharmaceutical                    material      |   |                                                                 | 4,473   |                          |   | 3,552 |   |   | 921 |   |
| Plant                    Extractive and others  |   |                                                                 | 92,526  |                          |   | 80,778 |   |   | 11,748 |   |
|                                            |   |                                                                 |    |                          |   |   |   |   |   |   |
| TOTAL                                           |   | $                                                                    | 638,442 |                          | $      | 570,618 |   | $ | 67,824 |   |
|                                            |   |                                                                 |    |                          |   |   |   |   |   |   |

|                                            |   |                                                                 |    |                          |   |
|-------------------------------------------------|--------|----------------------------------------------------------------------|---------|-------------------------------|--------|
|                                            |   | For                    quarter endedSeptember                    30, |    | Increase                    / |   |
| Product                                         |   | 2005                                                                 |    | 2004                          |   | (Decrease) |   |
|                                            |   |                                                                 |    |                          |   |   |   |   |   |   |
| Pharmaceutical                    intermediates |   | $                                                                    | 392,789 |                          | $      | 409,966 |   | $ | (17,177 | ) |
| Pharmaceutical                    material      |   |                                                                 | 4,706   |                          |   | 3,162 |   |   | 1,544 |   |
| Plant                    Extractive and others  |   |                                                                 | 80,778  |                          |   | 70,522 |   |   | 10,256 |   |
| TOTAL                                           |   | $                                                                    | 478,273 |                          | $      | 483,650 |   | $ | (5,377 | ) |
|                                            |   |                                                                 |    |                          |   |   |   |   |   |   |

----

|                                            |   |                                                                 |      |                          |   |
|-------------------------------------------------|--------|----------------------------------------------------------------------|-----------|-------------------------------|--------|
|                                            |   | Nine                    months endedSeptember                    30, |      | Increase                    / |   |
| Product                                         |   | 2005                                                                 |      | 2004                          |   | (Decrease) |   |
|                                            |   |                                                                 |      |                          |   |   |   |
| Pharmaceutical                    intermediates |   | $                                                                    | 1,664,848 |                          | $      | 1,716,964 |   | $ | (52,116 | ) |
| Pharmaceutical                    material      |   |                                                                 | 5,070     |                          |   | 8,953 |   |   | (3,883 | ) |
| Plant                    Extractive and others  |   |                                                                 | 311,336   |                          |   | 58,213 |   |   | 253,123 |   |
| TOTAL                                           |   | $                                                                    | 1,981,254 |                          | $      | 1,784,130 |   | $ | 197,124 |   |
|                                            |   |                                                                 |      |                          |   |   |   |   |   |   |

|                                            |   |                                                                 |      |                          |   |
|-------------------------------------------------|--------|----------------------------------------------------------------------|-----------|-------------------------------|--------|
|                                            |   | Nine                    months endedSeptember                    30, |      | Increase                    / |   |
| Product                                         |   | 2005                                                                 |      | 2004                          |   | (Decrease) |   |
|                                            |   |                                                                 |      |                          |   |   |   |
| Pharmaceutical                    intermediates |   | $                                                                    | 1,349,318 |                          | $      | 1,506,703 |   | $ | (157,385 | ) |
| Pharmaceutical                    material      |   |                                                                 | 4,917     |                          |   | 7,699 |   |   | (2,782 | ) |
| Plant                    Extractive and others  |   |                                                                 | 217,741   |                          |   | 51,310 |   |   | 166,431 |   |
| TOTAL                                           |   | $                                                                    | 1,571,976 |                          | $      | 1,565,712 |   | $ | 6,264 |   |
|                                            |   |                                                                 |      |                          |   |   |   |   |   |   |

----

**INFLATION**

----

**CURRENCY        EXCHANGE FLUCTUATIONS**

**Item        3. Controls and Procedures**

**PART        II. OTHER INFORMATION**

**Item        1. Legal Proceedings: **

----

**Item        2 - Unregistered Sales of Equity Securities and Use of        Proceeds: **

**Item        3. Defaults Upon Senior Securities: **

**Item        4. Submission of Matters to a Vote of Security Holders:**

**Item        5. Other Information: **

----

**Item        6. Exhibits and Reports on Form 8-K**

| (a) | Exhibits |
|-----|----------|

|   |   |                                                                                                                                                                                                                                                                                                                           |
|--------|--------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   | 3.1    | Articles                  of Incorporation (1)                                                                                                                                                                                                                                                                                 |
|   |   |                                                                                                                                                                                                                                                                                                                           |
|   | 3.2    | 3.2                  ByLaws (1)                                                                                                                                                                                                                                                                                                |
|   |   |                                                                                                                                                                                                                                                                                                                           |
|   | 3.3    | Certificate                  of Amendment to Articles of Incorporation (2)                                                                                                                                                                                                                                                     |
|   |   |                                                                                                                                                                                                                                                                                                                           |
|   | 10.1   | Amended                  Agreement and Plan of Reorganization dated July 13, 2004                  (3)                                                                                                                                                                                                                         |
|   |   |                                                                                                                                                                                                                                                                                                                           |
|   | 10.2   | Agreement                  and Plan of Reorganization dated as of December 20, 2004 by and                  among                  Secured Data, Inc., Northwest Bio-Technic Inc., and the shareholders                  of                  Northwest Bio- Technic Inc.; and Convertible Promissory Note                  (3) |
|   |   |                                                                                                                                                                                                                                                                                                                           |
|   | 10.3.  | Amendment                  No. 1 to the Convertible Promissory Note Due June 30, 2005                  (4)                                                                                                                                                                                                                     |
|   |   |                                                                                                                                                                                                                                                                                                                           |
|   | 31.1   | Sarbanes                  Oxley Section 302 Certification                                                                                                                                                                                                                                                                      |
|   |   |                                                                                                                                                                                                                                                                                                                           |
|   | 31.2   | Sarbanes                  Oxley Section 302 Certification                                                                                                                                                                                                                                                                      |
|   |   |                                                                                                                                                                                                                                                                                                                           |
|   | 32.1   | Sarbanes                  Oxley Section 906 Certification                                                                                                                                                                                                                                                                      |
|   |   |                                                                                                                                                                                                                                                                                                                           |
|   | 32.2   | Sarbanes                  Oxley Section 906 Certification                                                                                                                                                                                                                                                                      |
|   |   |                                                                                                                                                                                                                                                                                                                           |
|   | 99.1   | Code                  of Ethics (2)                                                                                                                                                                                                                                                                                            |
|   |   |                                                                                                                                                                                                                                                                                                                           |

----

|  | (1) | Incorporated                  by Reference from the registration statement on form SB-2 filed                  on or about July 28, 2000. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------|

|  | (2) | Incorporated                  by Reference from the registrant's quarterly report on Form 10-qsb                  for the fiscal quarter ended March 31, 2004 filed on May 17,                  2004. |
|--|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  | (3) | Incorporated                  by Reference from registrant's current report on Form 8-k filed                  on August 11, 2004. |
|--|-----|------------------------------------------------------------------------------------------------------------------------------------|

|  | (4) | Incorporated                  by reference from the Current Report on Form 8-K filed on or about                  July 7,                  2005. |
|--|-----|--------------------------------------------------------------------------------------------------------------------------------------------------|

| (b) | The                  following reports on Form 8-K were                  filed: |
|-----|---------------------------------------------------------------------------------|

| ·   | February                  4, 2005 to report the resignation of Art Malone as a                  director. |
|--------------------|-----------------------------------------------------------------------------------------------------------|

| ·   | March                  11, 2005 to report the Transaction. |
|--------------------|------------------------------------------------------------|

| ·   | March                  18, 2005 to report the change in                  accountant. |
|--------------------|--------------------------------------------------------------------------------------|

| ·   | April                  7, 2005 to report the change in                  accountant. |
|--------------------|-------------------------------------------------------------------------------------|

| ·   | April                  22, 2005 to report the change in accountant. |
|--------------------|---------------------------------------------------------------------|

| ·   | May                  12, 2005 to report the Transaction. |
|--------------------|----------------------------------------------------------|

| ·   | June                  20, 2005 to report non-reliance on previously issued financial                  statements. |
|--------------------|-------------------------------------------------------------------------------------------------------------------|

| ·   | June                  22, 2005 to report non-reliance on previously issued financial                  statements. |
|--------------------|-------------------------------------------------------------------------------------------------------------------|

| ·   | July                  7, 2005 to report the amending of the Promissory                  Note. |
|--------------------|-----------------------------------------------------------------------------------------------|

----

SIGNATURES

|         |                                                                  |                                 |
|--------------|-----------------------------------------------------------------------|--------------------------------------|
|         | **HUIFENG                BIO-PHARMACEUTICAL TECHNOLOGY, INC.**        |
|    |                                                             |                            |
|         | By:                                                         | /s/ JING                AN WANG |
|         |                                                                       |
|         | Jing                  An WangChief Executive                  Officer |

----